Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + filgrastim + paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), paclitaxel (a taxane), and filgrastim (G-CSF, a growth factor). This regimen is primarily used in the treatment of breast and ovarian cancers. Cyclophosphamide damages DNA in rapidly dividing cells, paclitaxel stabilizes microtubules during cell division preventing cancer cell multiplication, and filgrastim stimulates neutrophil production to reduce the risk of infection during chemotherapy-induced neutropenia.
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on cyclophosphamide + filgrastim + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + filgrastim + paclitaxel.